List view / Grid view

Tagrisso (osimertinib)

Filter the results

 

news

AstraZeneca’s lung cancer drug receives full approval in the EU

27 April 2017 | By Niamh Marriott, Junior Editor

The European Commission (EC) has granted full marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

news

AstraZeneca lung cancer drug receives FDA approval

4 April 2017 | By Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR…

article

UPDATE: The Cancer Drugs Fund

1 March 2017 | By Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).

news

NICE recommends first drug for the Cancer Drugs Fund

4 October 2016 | By Niamh Louise Marriott, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF).

news

Expanded Phase II trial of savolitinib in NSCLC starts

20 June 2016 | By Victoria White, Digital Content Producer

A Phase II expansion of the ongoing TATTON trial has been initiated to evaluate savolitinib (AZD6094) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients.

news

EC approves osimertinib in EGFR T790M mutation-positive NSCLC

3 February 2016 | By Victoria White

The European Commission (EC) has granted conditional marketing authorisation for AstraZeneca's Tagrisso (AZD9291, osimertinib) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

news

Incyte and AstraZeneca announce new lung cancer trial collaboration

11 January 2016 | By Victoria White

Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…

news

CHMP issues positive opinion for Tagrisso (osimertinib)

18 December 2015 | By Victoria White

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of AstraZeneca’s Tagrisso (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small…